We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information for health professionals on the epidemiology, transmission and prevention of Chlamydia abortus which can cause stillbirth or abortion in humans.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
Guidelines for commissioners, screening providers and programme managers for NHS cervical screening.
The review of the safety of isotretinoin has concluded.
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.
Half a million women in England have accessed cheaper HRT - the main treatment for negative menopause symptoms - since last April.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.